Home>Topics>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. French developer of "peanut allergy patch" makes U.S. debut

    Headlines

    Wed, 22 Oct 2014

    PARIS, Oct 22 (Reuters) - French biotech firm DBV Technologies - developer of what it says is a breakthrough treatment for peanut allergy sufferers - makes its U.S. market debut on Wednesday, with a Nasdaq listing set to raise funds for further research.

  2. UPDATE 3-Third Point's Loeb urges breakup of biotech company Amgen

    Headlines

    Tue, 21 Oct 2014

    BOSTON, Oct 21 (Reuters) - Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent.

  3. Aptos Bio to begin trading in U.S.

    Headlines

    Tue, 21 Oct 2014

    Toronto-based clinical-stage biotech Aptose Biosciences will begin trading on the NASDAQ Capital Market on or about October 23 under the symbol "APTO." The company

  4. Molecular Partners puts IPO on hold, citing market conditions

    Headlines

    Tue, 21 Oct 2014

    ZURICH, Oct 21 (Reuters) - Swiss biotech company Molecular Partners said on Tuesday it had decided to put its initial public offering on hold until further notice due to unfavourable market conditions.

  5. Determining Biogen's Fair Value

    Headlines

    Tue, 21 Oct 2014

    By Jonathan Weber : Biogen Idec (NASDAQ: BIIB ) is one of the world's biggest biotechnology companies. Biogen has a market capitalization of $72.4 billion, trailing revenues of $8.3 billion and earnings of $2.14 billion. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. ...

  6. BRIEF-Sartorius Stedim Biotech reports 9 months net profit of 63.2 mln euros, up 14.5 pct

    Headlines

    Tue, 21 Oct 2014

    * Says 9 months net profit is 63.2 million euros, up 14.5 pct

  7. Soligenix: A Low Risk, High Return Biotech Stock

    Headlines

    Mon, 20 Oct 2014

    Soligenix: A Low Risk, High Return Biotech Stock

  8. Gilead: Stage Set For Rally

    Headlines

    Mon, 20 Oct 2014

    By Bret Jensen : It was an interesting trading week in the stock that holds the largest position within my own portfolio, biotech juggernaut Gilead Sciences (NASDAQ: GILD ). The stock has been a rock throughout the recent spike in the volatility in the

  9. End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies

    Headlines

    Mon, 20 Oct 2014

    Management and Research : October has historically been a weak month for biotech , with the Biotech Index underperforming the S&P 500 in 14 out the last 20 years. The current biotech sell-off was driven primarily by macro concerns and not sector

  10. U.S. IPO Weekly Recap: 5 IPOs Achieve Moderate Gains During The Market Slide And A Biotech Rejection

    Headlines

    Sun, 19 Oct 2014

    25 and the IPO market responded with postponed deals, slashed valuations and average returns. Forward Pharma, the largest biotech IPO in over 10 years, fell 17% on its first day . Yet even as the energy sector took a beating, natural gas MLP Dominion

« Prev12345Next »
Content Partners